Skip to main content

Table 2 Descriptive characteristics of the populations used in the follow-up association studies on incident cardiovascular (CVD) and coronary heart disease (CHD) events: Women’s Health Initiative (WHI) and Framingham Offspring Study (FOS)

From: DNA methylation biomarkers of myocardial infarction and cardiovascular disease

Variables WHI FOS CHD FOS CVD
N = 1863 NA N = 2266 NA N = 2123 NA
Age 64.2 (7.03) 0 65.7 (8.82) 0 65.3 (8.66) 0
Sex, female, n (%) 1863 (100) 0 1284 (56.7) 0 1206 (56.8) 0
CHD, n (%) 914 (49.1) 0 106 (4.68) 0 _ _
CVD, n (%) 984 (52.8) 0 _ _ 222 (10.5) 0
Smokers, n (%) 174 (9.46) 24 217 (9.62) 11 202 (9.56) 11
BMI, kg/m2* 29.8 (5.97) 11 28.1 (5.39) 8 28.0 (5.33) 6
Total cholesterol, mg/dl* 233 (42.3) 1 189 (36.2) 1 190 (35.8) 1
LDL-C, mg/dl* 152 (38.7) 31 107 (30.8) 2 108 (30.5) 2
HDL-C, mg/dl* 52.2 (13.2) 1 58.3 (18.3) 2 58.7 (18.3) 2
TG, mg/d 126 [93.0;176] 1 101 [73.0;140] 1 100 [73.0;139] 1
SBP, mmHg* 131 (17.5) 0 126 (16.9) 1 125 (16.7) 1
DBP, mmHg* 76.4 (9.27) 0 72.1 (9.99) 3 72.3 (9.92) 3
HTN treatment, n (%) 672 (45.9) 400 1025 (45.4) 7 927 (43.8) 6
Glucose, mg/dl 107 (38.3) 1 106 (21.8) 2 105 (21.5) 2
Diabetes, n (%) 319 (17.1) 0 307 (14.3) 126 266 (13.3) 119
  1. CHD, Coronary heart disease; CVD, Cardiovascular disease; BMI, Body mass index; LDL-C, Cholesterol in low-density lipoprotein; HDL-C, Cholesterol in high-density lipoprotein; TG, Triglycerides; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; HTN: hypertension; Diabetes, defined as previous treatment or glycaemia ≥ 126 mg/dl
  2. Median (Interquartile range)
  3. *Mean (Standard deviation)